Equity Overview
Price & Market Data
Price: $0.80
Daily Change: +$0.0101 / 1.26%
Daily Range: $0 - $0
Market Cap: $350,106,560
Daily Volume: 0
Performance Metrics
1 Week: -6.98%
1 Month: 7.37%
3 Months: -16.62%
6 Months: 24.61%
1 Year: 28.37%
YTD: 7.37%
Details
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that drives localization to fibroblast activation protein expressing tumors. The company was incorporated in 2003 and is headquartered in London, the United Kingdom.